[From bench to bedside for new treatment paradigms in chordomas: An update].
Depuis la recherche translationnelle jusqu’aux nouveaux paradigmes thérapeutiques : mise à jour des données dans les chordomes.
Chirurgie
Chordomas
Chordomes
Immunotherapy
Immunothérapie
Radiotherapy
Radiothérapie
Surgery
Targeted therapies
Thérapies ciblées
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
05
06
2019
revised:
25
10
2019
accepted:
30
10
2019
pubmed:
29
12
2019
medline:
28
2
2020
entrez:
29
12
2019
Statut:
ppublish
Résumé
Chordomas are rare malignant tumours, which typically occur in the axial skeleton and skull base. They arise from embryonic remnants of the notochord. They constitute less than 5 % of primary bone tumours. They are characterised by their locally aggressive potential with high frequency of recurrences and a median overall survival of 6 years. The initial therapeutic strategy must be discussed in an expert centre and may involve surgery, preoperative radiotherapy, exclusive radiotherapy or therapeutic abstention. Despite this, more than 50 % of patients will be facing recurrences with few therapeutic options available at this advanced stage. This review aims to outline current treatment options available in chordomas, as well as discussing potentiality of new therapeutic approaches through their molecular characterization and the comprehension of their immunological environment.
Identifiants
pubmed: 31882268
pii: S0007-4551(19)30412-6
doi: 10.1016/j.bulcan.2019.10.008
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Neoplasm Proteins
0
Types de publication
Journal Article
Langues
fre
Sous-ensembles de citation
IM
Pagination
129-135Informations de copyright
Copyright © 2019 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.